In some studies which have reported the efficacy of continuation therapy with first‐generation EGFR‐TKIs including G and erlotinib beyond PD for advanced EGFR‐mutant NSCLC,17, 42, 43, 44, 45 the continuation of EGFR‐TKIs until symptomatic progression was beneficial for patients with EGFR‐mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.